Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2008 1
2009 3
2010 2
2011 4
2012 6
2013 5
2014 3
2015 1
2016 4
2017 4
2018 5
2019 1
2020 10
2021 7
2022 8
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
van den Heerik ASVM, Horeweg N, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld GH, van den Berg HA, Slot A, Koppe FLA, Kommoss S, Mens JWM, Nowee ME, Bijmolt S, Cibula D, Stam TC, Jurgenliemk-Schulz IM, Snyers A, Hamann M, Zwanenburg AG, Coen VLMA, Vandecasteele K, Gillham C, Chargari C, Verhoeven-Adema KW, Putter H, van den Hout WB, Wortman BG, Nijman HW, Bosse T, Creutzberg CL. van den Heerik ASVM, et al. Among authors: vandecasteele k. Int J Gynecol Cancer. 2020 Dec;30(12):2002-2007. doi: 10.1136/ijgc-2020-001929. Epub 2020 Oct 12. Int J Gynecol Cancer. 2020. PMID: 33046573 Free PMC article.
Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction.
Tulkens J, Vergauwen G, Van Deun J, Geeurickx E, Dhondt B, Lippens L, De Scheerder MA, Miinalainen I, Rappu P, De Geest BG, Vandecasteele K, Laukens D, Vandekerckhove L, Denys H, Vandesompele J, De Wever O, Hendrix A. Tulkens J, et al. Among authors: vandecasteele k. Gut. 2020 Jan;69(1):191-193. doi: 10.1136/gutjnl-2018-317726. Epub 2018 Dec 5. Gut. 2020. PMID: 30518529 Free PMC article. No abstract available.
Immunogenic Apoptotic Cell Death and Anticancer Immunity.
Vandenabeele P, Vandecasteele K, Bachert C, Krysko O, Krysko DV. Vandenabeele P, et al. Among authors: vandecasteele k. Adv Exp Med Biol. 2016;930:133-49. doi: 10.1007/978-3-319-39406-0_6. Adv Exp Med Biol. 2016. PMID: 27558820 Review.
TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?
De Meulenaere A, Vermassen T, Aspeslagh S, Vandecasteele K, Rottey S, Ferdinande L. De Meulenaere A, et al. Among authors: vandecasteele k. Head Neck Pathol. 2017 Sep;11(3):354-363. doi: 10.1007/s12105-016-0776-8. Epub 2016 Dec 28. Head Neck Pathol. 2017. PMID: 28032290 Free PMC article. Review.
A clearer view on ovarian clear cell carcinoma.
De Pauw A, Naert E, Van de Vijver K, Philippe T, Vandecasteele K, Denys H. De Pauw A, et al. Among authors: vandecasteele k. Acta Clin Belg. 2022 Aug;77(4):792-804. doi: 10.1080/17843286.2021.1964051. Epub 2021 Aug 17. Acta Clin Belg. 2022. PMID: 34404331
Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study.
Fonteyne V, Danckaert W, Ost P, Berghen C, Vandecasteele K, Vanneste B, Rans K, Liefhooghe N, Wallaert S, Paelinck L. Fonteyne V, et al. Among authors: vandecasteele k. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231154088. doi: 10.1177/15330338231154088. Technol Cancer Res Treat. 2023. PMID: 37016933 Free PMC article. Clinical Trial.
Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.
Makar AP, Tropé CG, Tummers P, Denys H, Vandecasteele K. Makar AP, et al. Among authors: vandecasteele k. Oncologist. 2016 Jun;21(6):745-54. doi: 10.1634/theoncologist.2015-0239. Epub 2016 Mar 23. Oncologist. 2016. PMID: 27009938 Free PMC article. Review.
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.
De Jaeghere EA, Tuyaerts S, Van Nuffel AMT, Belmans A, Bogaerts K, Baiden-Amissah R, Lippens L, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, Van de Vijver KK, Amant F, Vandecasteele K, Denys HG. De Jaeghere EA, et al. Among authors: vandecasteele k. Cancer Immunol Immunother. 2023 Feb;72(2):475-491. doi: 10.1007/s00262-022-03253-x. Epub 2022 Aug 12. Cancer Immunol Immunother. 2023. PMID: 35960332 Free PMC article. Clinical Trial.
62 results